392 material Form 8-K filings that 341 companies we cover made with the SEC in July 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
AMERISAFE reported second-quarter 2024 net income of $11.0 million, down 29.7% from $15.6 million a year earlier, and diluted EPS of $0.57, down from $0.81. Net premiums earned rose 4.6% to $68.6 million, but higher loss and expense costs cut underwriting profit by 31.2% to $6.5 million, so shareholders saw lower per-share earnings even as the insurer wrote more business.
Diluted EPS was $0.57 for the quarter, versus $0.81 in Q2 2023; operating EPS was $0.58, versus $0.73.
Net premiums earned rose 4.6% to $68.6 million, while the net combined ratio worsened to 90.5% from 85.4%.
Favorable prior accident year reserve development reduced loss expenses by $8.1 million.
The Board declared a quarterly dividend of $0.37 per share on July 26, 2024, payable September 20, 2024; a conference call is set for July 30, 2024.
Rambus reported second-quarter 2024 results for the period ended June 30, 2024, with GAAP revenue of $132.1 million, up from $119.8 million a year earlier, and operating income of $40.3 million, up from $11.7 million. Net income fell to $36.1 million, or $0.33 per diluted share, from $168.9 million, or $1.51, a year earlier, when the company recorded an income tax benefit of $155.3 million. Shareholders get higher revenue and operating income, but reported earnings declined against a prior-year period that included that tax benefit, and the company said it expects a strong third quarter.
GAAP revenue was $132.1 million versus $119.8 million in Q2 2023; product revenue was $56.7 million and royalties were $56.4 million.
Net income was $36.1 million, or $0.33 per diluted share, versus $168.9 million, or $1.51, in Q2 2023, which included a $155.3 million income tax benefit.
Cash from operating activities was $70.4 million, versus $50.4 million a year earlier; cash and marketable securities totaled $432.9 million at June 30, 2024.
Third-quarter 2024 outlook calls for product revenue of $62 million to $68 million and licensing billings of $60 million to $66 million; full revenue guidance will be discussed on the conference call.
Lattice Semiconductor reported second-quarter 2024 revenue of $124.1 million, down 11.9% from the first quarter and 34.7% from a year earlier, with GAAP diluted earnings of $0.16 per share. The company guided third-quarter 2024 revenue to between $117 million and $137 million, and interim CEO Esam Elashmawi said the industry is starting to show signs of improvement after a period of inventory normalization.
Q2 2024 revenue was $124.1 million, down 11.9% from Q1 2024 and down 34.7% from Q2 2023.
GAAP diluted EPS was $0.16 versus $0.11 in Q1 2024 and $0.36 in Q2 2023; non-GAAP diluted EPS was $0.23 versus $0.29 in Q1 2024.
Q3 2024 outlook: revenue of $117 million to $137 million, non-GAAP gross margin of 69.0% plus or minus 1%, and non-GAAP operating expenses of $53 million to $55 million.
The company repurchased shares for the fifteenth consecutive quarter, with $30.0 million of buybacks in the first half of 2024.
Minerals Technologies furnished the transcript and slides from its July 26, 2024 second-quarter earnings call as Exhibits 99.1 and 99.2, because a third-party webcast problem meant some listeners could not hear part of the audio. The call showed higher operating income and earnings per share excluding special items, offset by $34 million in special charges, mainly a $30 million provision for a credit loss on a line of credit to BMI Oldco, the entity formerly known as BMI.
Q2 2024 sales were $541 million, up 1% on an underlying basis; operating income was $85 million, up 20%, with operating margin of 15.7%.
Earnings per share were $1.65 excluding special items, up 26% from the prior year; special charges totaled $34 million.
The $34 million in special charges mainly reflects a $30 million provision for credit loss on a committed line of credit to BMI Oldco, of which $5 million has been loaned so far.
For Q3 2024, the company expects sales of $535 million to $545 million, operating income of $77 million to $80 million, and EPS of $1.50 to $1.55.
Revvity reported second-quarter 2024 revenue of $692 million, down from $709 million a year earlier, while GAAP EPS rose to $0.45 from $0.28 and adjusted EPS from continuing operations was $1.22 versus $1.21. The company raised its full-year 2024 adjusted EPS guidance to $4.70-$4.80 and set revenue guidance at $2.77-$2.79 billion, citing currency changes and assumed 2% organic revenue growth. Shareholders see higher profit measures alongside a lower top line, with Life Sciences revenue down 7%.
Q2 2024 revenue was $692 million versus $709 million a year earlier; reported revenue fell 2% and organic revenue fell 1%.
GAAP EPS was $0.45 versus $0.28; adjusted EPS from continuing operations was $1.22 versus $1.21.
Full-year 2024 adjusted EPS guidance raised to $4.70-$4.80; revenue guidance updated to $2.77-$2.79 billion.
Life Sciences revenue fell 7% to $314 million; Diagnostics revenue rose 1% to $378 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.